Cannabinoid penetration into mouse brain as determined by ex vivo binding

Petitet, François; Jeantaud, Bernadette; Bertrand, Philìppe; Impérato, Assunta

doi:10.1016/s0014-2999(99)00189-2

Cited by 29 publications

(21 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Δ 9 -THC was shown to decrease rate of responding for food in wildtype C57BL/6J mice and not transgenic mice lacking CB 1 receptors, whereas methanandamide produced similar decreases in rate of responding in both wildtype and CB 1 knockout mice (Baskfield et al 2004). These results do not appear to reflect inability of methanandamide to bind to CB 1 receptors in mouse brain inasmuch as a previous study (Petitet et al 1999) reported that methanandamide binds to cannabinoid receptors in mouse brain after i.p. administration at the doses and interval of pretreatment chosen for the present study.…”

Section: Discussioncontrasting

confidence: 70%

Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Δ9-tetrahydrocannabinol in C57BL/6J mice

2007

View full text Add to dashboard Cite

The discriminative stimulus effects of Delta(9)-THC, CP 55940, and WIN 55212-2 are mediated by the same (i.e., CB(1)) receptors, whereas the effects of methanandamide or a metabolite of methanandamide are mediated at least in part by non-CB(1) receptors. The discriminative stimulus effects of Delta(9)-THC in mice could be used to evaluate mechanisms of cannabinoid activity with approaches (e.g., inducible knockouts) currently unavailable in nonmurine species.

show abstract

Section: Discussioncontrasting

confidence: 70%

Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Δ9-tetrahydrocannabinol in C57BL/6J mice

2007

View full text Add to dashboard Cite

show abstract

“…It should be mentioned that the observed increase in the hippocampus was more robust as compared to the rest of the regions studied. These alterations in dopaminergic activity cannot be attributed to the last administration of WIN 55,212-2 since this dose was delivered 24 h earlier and the drug action has been eliminated according to our unpublished behavioural observations and related findings by Petitet et al (1999).…”

Section: Discussionmentioning

confidence: 89%

Behavioural and dopaminergic alterations induced by a low dose of WIN 55,212-2 in a conditioned place preference procedure

et al. 2009

View full text Add to dashboard Cite

“…Our data showed that WIN 55,212-2 was not able to affect the serum TSH levels at any of the analyzed time-points (30 min, 1 h, 2 h, 4 h); however, we cannot exclude the possibility that a decrease in TSH levels could occur later than 4 h after WIN 55,212-2 administration. The fact that in a previous study D 9 THC was able to decrease TSH levels very rapidly (1) shows that D 9 THC and WIN 55,212-2, having different pharmacokinetic and metabolic profiles (8,23,24), can act on the pituitary CB1 receptors with divergent mechanisms of action.…”

Section: Discussionmentioning

confidence: 94%

Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid

Porcella

Marchese²,

Casu³

et al. 2002

Eur J Endocrinol

View full text Add to dashboard Cite

Objective: Previous reports have shown that the D 9 -tetrahydrocannabinol (D 9 TCH), the major psychoactive cannabinoid components of marijuana, is unable to inhibit thyroid hormonal activity. The aim of this study was to characterize the CB1 functional expression in the rat thyroid by a multi-methods approach. Methods and Results: RT-PCR was used to detect the mRNA expression of the CB1 cannabinoid receptor (17:8^4:0% of the normalizing reference gene b 2 microglobulin), as well as the expression of the endocannabinoid hydrolyzing enzyme, fatty acid amide hydrolase (46:9^4:3% of b 2 microglobulin), in the rat thyroid gland.The CB1-encoded protein was detected in its glycosylated form (63 kDa) by Western blot, employing a polyclonal antibody, while CB1 immunohistochemical localization showed an intracellular positive staining in both follicular and parafollicular cells. In addition, a 30% decrease in serum levels of both 3,5,3 0 tri-iodothyronine (T 3 ) and thyroxine (T 4 ) was detected 4 h after the administration of the synthetic cannabinoid receptor agonist, WIN 55,212-2 (10 mg/kg i.p.). These effects were antagonized by pretreatment with the CB1 antagonist SR 141716A (3 mg/kg i.p.); thyrotrophin levels were unaffected by both treatments. Conclusion: These data indicate that functional CB1 receptors which are able to modulate the release of T 3 and T 4 are expressed in the rat thyroid, and suggest a possible role of cannabinoids in the regulation of rat thyroid hormonal activity.

show abstract

Cannabinoid penetration into mouse brain as determined by ex vivo binding

Cited by 29 publications

References 13 publications

Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Δ9-tetrahydrocannabinol in C57BL/6J mice

Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Δ9-tetrahydrocannabinol in C57BL/6J mice

Behavioural and dopaminergic alterations induced by a low dose of WIN 55,212-2 in a conditioned place preference procedure

Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid

Contact Info

Product

Resources

About